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Coordination of different complexes to copper(II) and cobalt(III) metal centers 
enhances Zika virus and dengue virus loads in both arthropod cells and 
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Trace elements such as copper and cobalt have been associated with virus-host 
interactions. However, studies to show the effect of conjugation of copper(II) or cobalt(III) metal 
centers to thiosemicarbazone ligand(s) derived from either food additives or mosquito repellent 
such as 2-acetylethiazole or citral, respectively, on Zika virus (ZIKV) or dengue virus (serotype 
2; DENV2) infections have not been explored. In this study, we show that four compounds 
comprising of thiosemicarbazone ligand derived from 2-acetylethiazole viz., (E)-N-ethyl-2-[1-
(thiazol-2-yl)ethylidene]hydrazinecarbothioamide (acetylethTSC) (compound 1), a copper(II) 
complex with acetylethTSC  as a ligand (compound 2), a thiosemicarbazone ligand-derived from 
citral (compound 3) and a cobalt(III) complex with a citral-thiosemicarbazone ligand- 
(compound 4) increased DENV2 and ZIKV replication in both mosquito C6/36 cells and human 
keratinocytes (HaCaT cells). Treatment of both cell lines with compounds 2 or 4 showed 
increased dengue viral titers at all three tested doses.  Enhanced dengue viral plaque formation 
was also noted at the tested dose of 100 µM, suggesting higher production of infectious viral 
particles. Treatment with the compounds 2 or 4 enhanced ZIKV and DENV2 RNA levels in 
HeLa cell line and primary cultures of mouse bone marrow derived dendritic cells. Also, pre- or 
post treatments with conjugated compound 2 or 4 showed higher loads of ZIKV or DENV2 
envelope (E) protein in HaCaT cells. No changes in loads of E-protein were found in ZIKV-
infected C6/36 cells, when compounds were treated after infection. In addition, we tested 
bis(1,10-phenanthroline)copper(II) chloride ([Cu(phen)2]Cl2, (compound 5) and tris(1,10-
phenanthroline)cobalt(III) chloride ([Co(phen)3]Cl3, (compound 6) that also showed enhanced 













chloride hexahydrate (CoCl2•6H2O) alone had no effects as “free” cations. Taken together, these 
findings suggest that use of Cu(II) or Co(III) conjugation to organic compounds, in insect 
repellents and/or food additives could enhance DENV2/ZIKV loads in human cells and perhaps 
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Mosquito-borne diseases are of great concern to the mankind. Use of chemicals/repellents 
against mosquito bites and transmission of microbes has been the topic of interest from many 
years. Here, we show that thiosemicarbazone ligand(s) derived from 2-acetylethiazole or citral or 
1,10-phenanthroline upon conjugation with copper(II) or cobalt(III) metal centers enhances 
dengue virus (serotype 2; DENV2) and/or Zika virus (ZIKV) infections in mosquito, mouse and 
human cells. Enhanced ZIKV/DENV2 capsid mRNA or envelope protein loads were evident in 
mosquito cells and human keratinocytes, when pre-treated with compounds before/after 
infections. Also, treatment with copper(II) or cobalt(III) conjugated compounds increased viral 
titers and number of plaque formations. These studies suggest that conjugation of compounds in 
repellents/essential oils/natural products/food additives with copper(II) or cobalt(III) metal 
centers may not be safe, especially in tropical and subtropical places, where several dengue 
























Insect bites, food or crop damage and transmission of pathogens to humans, animals and 
plants has led to the extensive use of insecticides, pesticides and insect attractants or repellents 
[1,2]. Use of these substances has substantially been increased in military personnel and in 
agriculture or horticulture practices. Over a decade, several of these chemicals have been used 
extensively in all parts of the world. Some synthetic compounds or chemicals are of major 
concern to the environment and human health and they have been withdrawn due to the adverse 
effects and serious human health hazards [3-8]. One of the most recent study tested that several 
of the repellents including citronella candles had no effects and did not reduced mosquito 
attraction to humans [9].  The disadvantages of some insecticides have promoted the use of 
plant-based essential oils and their derived natural products, belonging to several herb species 
that poses repellent activities [7,10]. Some of the essential oils, herbal skin products and non-
natural inorganic insecticides (the contact insecticides that are toxic to insects upon direct 
contact) have been shown to contain metals such as arsenates, copper, cobalt and fluorine 
compounds in small amounts and sulfur as a major component [11]. Also, both copper sulfate 
and cobalt chloride has been shown to improve the varieties in rice and vegetables that are 
mostly consumed in Australia and some parts of Asia [12]. In addition, complex mixtures of 
volatile organic compounds produced from plant-based essential oils or natural products such as 
citral have been extensively used as repellents to prevent transmission of human pathogens 














 Mosquitoes are the primary vectors responsible for the transmission of arthropod-borne 
flaviviruses that cause microcephaly (Zika Virus), dengue hemorrhagic fever, yellow fever, West 
Nile neuroinvasive disease (WNND) and Japanese encephalitis. With regard to the global impact 
from arthropod-borne diseases, dengue is the most important human pathogen (that exist as four 
serotypes; DENV-1, 2, 3 and 4) that should be addressed promptly. According to the 2009 WHO 
criteria, dengue cases have been classified according to the levels of severity. Dengue infections 
without warning signs or with warning signs (such as abdominal pain, persistent vomiting, fluid 
accumulation, mucosal bleeding, liver enlargement, increasing hematocrit with decreased platelet 
numbers and lethargy) were considered as less severe. However, dengue infections with severe 
plasma leakage, bleeding or organ failures were considered as severe cases [14,15]. 
Approximately 20,000-25,000 deaths and 50-100 million dengue infections with 500,000 
hospitalizations are reported, annually [16]. Also, there are no fully effective vaccines available 
for human use and prevention of dengue [17,18]. Nevertheless, recently, WHO immunization 
group (Strategic Advisory Group of Experts; SAGE) has recommended the use of partially 
effective dengue vaccine (a live attenuated tetravalent dengue vaccine developed by Sanofi 
Pasteur; CYD-TDV, named Dengvaxia) that has been licensed and used in 11 countries 
including Brazil, Mexico, Singapore, Thailand and Indonesia [19]. Related to dengue, Zika virus 
(ZIKV) is an emerging infectious agent transmitted and spread by the daytime active Aedes 
mosquitoes, such as A. aegypti and A. albopictus. ZIKV can be transmitted by blood 
transfusions, sexual and placental leakage from the mother to the fetus [20,21]. An important 
public health concern has been declared due to global epidemic of ZIKV infections.  The 
association between ZIKV infection during pregnancy and intrauterine fetal infection, 













models of fetal infections are reported [20-22]. The best prevention practice is the use of 
mosquito nets, protective clothing such as long-sleeve shirts and full pants and insect repellents 
to avoid the mosquito bites. In high endemic areas, it becomes important to use repellents on a 
routine basis to prevent bites from infected mosquitoes. 
 
Several reports suggest that trace elements such as copper and cobalt play an important 
role in the host immunomodulatory activities during viral infections [23,24]. Any changes in the 
levels of trace elements could impact disease severity [25]. Essential oils from plants and herbs 
can inactivate enveloped and non-enveloped viral replication and exhibit antiviral activities [26-
29]. Due to the strong antiviral and antimicrobial activities, novel citral-based compounds (the 
well-known natural insect repellent) are developed continuously [26-29]. Studies that show the 
effect of conjugation of citral-based compounds with different trace elements on ZIKV and 
dengue virus replication has not been explored.  The purpose of the current study is to analyze 
the effects of copper(II) and cobalt(III) metal conjugations with organic compounds (that are 
used in repellents or food additives) on DENV2/ZIKV infections. The four compounds analyzed 
in this study are selected based on the structural activity relationship (SAR) in order to determine 
the best efficacy in inhibition of the virus. It has been reported that when “free” 
thiosemicarbazone ligands are coordinated to a metal center, the efficacy in the activity is 
enhanced in comparison to the “free” ligands. In this study, we show that treatment of mosquito 
(C6/36 cells) and human keratinocytes (HaCaT cells), HeLa cells and primary cultures of mouse 
bone marrow derived dendritic cells with thiosemicarbazones coordinated to Cu(II) or Co(III) 













version with metal centers in the repellent formulations may aid better replication of ZIKV and 


































MATERIALS AND METHODS  
 
Synthesis of the ligands and the compounds. Analytical or reagent grade chemicals were used 
throughout this study. All the chemicals including solvents were obtained from Sigma-Aldrich 
(St. Louis, MO, U.S.A.) or other commercial vendors, and used as received. Microanalyses (C, H, 
N) were performed by Intertek Chemical and Pharmaceuticals, 291 Route 22 East, Salem 
Industrial Park, Building #5, Whitehouse, NJ 08888, U.S.A.  The FT IR (Fourier Transform 
infrared) spectrum was acquired in the range of 4000-400 cm
-1
 using the Attenuated Total 
Reflectance (ATR) accessory (with a diamond crystal) on a Nicolet 6700 FT IR spectrometer.  
1
H nuclear magnetic resonance (
1
H NMR) spectra were acquired on a Bruker AVANCE III 400 
MHz spectrometer with deuterated dimethyl sulfoxide-d6 (DMSO-d6) as solvent.  All 
1
H NMR 
spectra were processed with the Spectrus Processor 2012 software, which is available from 
Advanced Chemistry Development (ACD, Inc., 8 King Street East, Suite 107, Toronto, Ontario 
M5C 1B5, Canada).   
 
The “free” salts and complexes. 
The “free” CuCl2.2H2O and CoCl2.6H2O salts were obtained from Sigma-Aldrich Corporation. 
Synthesis of (E)-N-ethyl-2-[1-(thiazol-2-yl)ethylidene]hydrazinecarbothioamide (acetylethTSC) 1 
and [Cu(acetylethTSC)Cl]Cl0.25C2H5OH 2  (Compounds 1 and 2, respectively) 
(E)-N-ethyl-2-[1-(thiazol-2-yl)ethylidene]hydrazinecarbothioamide (acetylethTSC) 1 was 
synthesized and characterized as by Lewis et al.; [30] while the complex, 













yl)ethylidene]hydrazinecarbothioamide) was synthesized and characterized as by Sandhaus et al. 
[31]. 
Synthesis of citralEtTSC0.25C2H5OH 3 (Compound 3) 
Citral (3.0 g, 3.377 ml, 20 mmol) and 4-ethyl-3-thiocarbazide (2.4 g, 20 mmol) were mixed in a 
250 ml round bottom flask, followed by anhydrous ethanol (100 ml) and five drops of glacial 
acetic acid.  The reaction mixture was refluxed with stirring for three hours and evaporated to 
dryness.  The resulting oil was allowed to stay at room temperature until it solidified to leave the 
resulting product.  Yield = 4.8 g (91%).  Calc. C13.5H24.5N3O0.25S, C, 61.21; H, 9.32; N, 15.86%.  
Found: C, 60.82; H, 9.34; N, 15.76%.  FT IR (/cm
-1
): 3164 (m) (-N
1
H), 3054 (m) (-N
2
H), 1059 
(m) (N-N), 1543 (m) (TSC (C=N)), (1296) (m) and (813) (m) (C=S).  
1
H NMR (400 MHz; 
DMSO-d6); H = 1.16 (t, J
t
 = 7.10 Hz, 3H, -CH3), 2.42 (s, 3H, CH3CH=N), 3.61 (d, 2H, CH2), 
7.79 (d, J
d
 = 3.21 Hz, CHar), 7.88 (d, J
d
 = 3.19 Hz, CHar), 8.08 (d, J
d
 = 3.24 Hz, CHar), 8.30 (s, H, 
aminic NH), 10.58 (s, 1H, hydrazinic-NH), and 13.2 (s, H-bonded hydrazinic-NH) ppm. 
Synthesis of [Co(phen)2(citralEtTSC)](NO3)30.25H2O1.5C2H5OH 4 (Compound 4) 
At first, [Co(phen)2CO3]Cl5H2O was synthesized using the procedure as reported by 
Kashiwabara et al. [32]. First, we prepared [Co(phen)2(H2O)2](NO3)3, then 
[Co(phen)2(H2O)2](NO3)32H2O was synthesized by the acid hydrolysis of 
[Co(phen)2CO3]Cl5H2O using the synthesis as reported by Ye et al. [33]. Finally, 
[Co(phen)2(H2O)2](NO3)32H2O was placed in an oven set at 110 C for 24 hours in order to 
produce anhydrous [Co(phen)2(H2O)2](NO3)3. [Co(phen)2(H2O)2](NO3)3 (0.80 g, 1.2 mmol) and 
citralEtTSC0.25C2H5OH (0.32 g, 1.2 mmol) in anhydrous ethanol (410 ml) were refluxed in a 
500 ml round bottom flask with stirring at 110 °C under argon for 24 hours.  The mixture was 













Calc. C40H48.5CoN10O10.75S, C, 51.53; H, 5.24; N, 15.02%.  Found: C, 51.53; H, 4.57; N, 14.57%.  
Complexes 5 and 6, [Cu(phen)2]Cl2 and [Co(phen)3]Cl3 were synthesized respectively as by the 
literature procedure [34,35].  
All tested compounds were completely solubilized in DMSO and were prepared as 1 ml 
of 100 mM solutions (compounds 1, 3 and 4) or 20 mM stocks of compound 2 (due to low 
solubility issues) or 0.1 mM stock of Compound 5 and 6 were prepared. The indicated doses 1, 
10 and 100 µM were prepared from the stock solutions and used as test doses throughout the 
study. The compound stocks and dilutions were kept as recommended by the previous studies. 
 
Cell Culture and Infection. Mosquito (C6/36) cells and Vero (African Green Monkey kidney) 
cell line were purchased from American Type Culture Collection (ATCC). Human keratinocytes 
(HaCaT cells) were obtained from Dr. Loree Heller, Center for Bioelectrics. C6/36 or HaCaT 
cells were plated in a 24/12 well plate at a density of 1 x 10
5
 cells per well in complete MEM or 
DMEM medium containing 10% FBS, L-glutamine and Pen/Strep and kept at either 30º C or 37 
º C with 5% CO2, respectively. Cells were either treated with respective compounds 1, 2, 3 or 4 
(with indicated doses; 1, 10 or 100 µM) for 24 hours before or after infection with 
ZIKV/DENV2 (multiplicity of infection, MOI = 1) for 24-hour. Compounds 5 and 6 or the 
“free” Cu(II) and Co(III) salts (with indicated doses; 1, 10 or 100 µM) were also treated for 24 
hours followed by infection with DENV2 (multiplicity of infection, MOI = 1) for another 24-
hour. ZIKV strain, VR-1838, was obtained from ATCC or DENV2 (Serotype 2); El Salvador 
TVP2176 strain was obtained from Dr. John F. Anderson, Connecticut Agricultural Experiment 














RNA extraction, cDNA synthesis and Quantitative Real-time PCR (Q-PCR) Analysis. Total 
RNA from (1 x 10
5
) of either C6/36 cells or HaCaT cells, first treated with the compounds (for 
24 hours) using different doses (1, 10 or 100 µM) followed by infection with DENV2/ ZIKV 
(MOI 1; 24 hour post infection) or post-treated (24 hours) with respective compounds (indicated 
doses) after DENV2/ZIKV infection (MOI 1; 24 hours) were generated using Aurum Total RNA 
Mini kit (BioRad, Hercules, CA) following manufacturer instructions. RNA was converted to 
cDNA using iScript cDNA synthesis kit (BioRad).  The generated cDNA was used as template 
for the amplification of DENV2/ZIKV; capsid/NS5 transcripts, respectively, from cDNA with 
primers as described [36,37]. As an internal control and to normalize the amount of template, 
either mosquito or mouse or human beta actin amplicons were quantified using published 
primers [36]. Q-PCR data showing DENV2/ZIKV loads were presented by normalizing 
expression of capsid/ NS5 gene transcripts to either mosquito or mouse or human beta actin. Q-
PCR was performed using iQ-SYBR Green Supermix and CFX96 touch System (BioRad).  
Standard curves were prepared using 10-fold serial dilutions starting from 1 to 0.00001 ng/µl of 
known quantities of DENV2/ ZIKV, capsid/ NS5, and respective beta-actin fragments. Following 
are the oligonucleotides used in this study: DENV2 capsid, 5’ 
AATATGCTGAAACGCGAGAGAAACCGCG 3’ and 5’ CTCTTCAGTATCCCTGCTGTTGG 
3’; ZIKV NS5, 5’ AARTACACATACCARAACAAAGTGGT 3’ and 5’ 
TCCRCTCCCYCTYTGGTCTTG 3’; human actin, 5’ AGCCTCGCCTTTGCCGA 3’ and 5’ 
CTGGTGCCTGGGGCG 3’; mouse actin, 5’ CCCTAGGCACCAGGGTGTGA 3’ and 5’ 
GGGGTGTTGAAGGTCTCAAACA 3’; mosquito actin, 5’ CCATGTACGTCGCCATCCA 3’ 
and 5’ GCGGTGGCCATTTCCTG 3’; human IFN-beta, 5’ 













human TNF-alpha, 5’ CCCAGGCAGTCAGATCATCTT 3’ and 5’ 
TCTCAGCTCCACGCCATT 3’. 
 
Western Blotting. Total proteins from 1 x 10
5 
of either C6/36 cells or HaCaT cells infected with 
DENV2 (MOI 1; 24 hour post infection) or with ZIKV (MOI 1 or 5; for 24 hour) and then 
followed by treatments with respective compounds at different doses (1, 10, 100 µM) for another 
24-hour period or vice versa (treated with compounds and then infected; in a similar manner as 
described above) were collected in ice-cold modified RIPA buffer (G-Biosciences, BioExpress, 
Kaysville, UT). Total proteins were estimated using BCA kit (Pierce, ThermoScientific). Total 
lysates from C6/36 or HaCaT cells (25 µg) were separated on 4-20% gradient or 12% SDS-
PAGE gels (NuSep; BioExpress). Following gel electrophoresis, blotting (on nitrocellulose 
membranes) and blocking (5% milk buffer or BSA NAP-blocker solution; G-Biosciences, 
BioExpress) was processed and blots were incubated with 4G2 primary antibody (non-reducing 
conditions), obtained from Dr. Michel Ledizet, L2 Diagnostics, Inc. Monoclonal Anti-Flavivirus 
Group Antigen, Clone D1-4G2-4-15 (Catalog Number; NR-50327), antibody obtained from BEI 
resources was used to detect ZIKV E-protein. Mouse monoclonal IgG conjugated with HRP 
(Santa Cruz Biotechnologies, Dallas, TX) were used as secondary antibodies for detection. Total 
protein profiles serve as loading controls and not for comparison between the compounds. The 
differences in protein profile gels are due to use of either stain-free gels images after run, or 
staining of gels with either colloidal Coomassie blue or R-250 Coomassiee blue solutions. ECL 
detection of antibody binding was performed with WesternBright ECL kit (Advansta, 
BioExpress). Blots were scanned using Chemidoc MP imaging system and recommended Image 














Virus Titration Assays. For the titration assay, briefly, C6/36 or HaCaT cells were seeded into 
96 well plates and at a density of 1 x 10
5
 cells/well in 225 µl of either MEM or DMEM complete 
medium with 10% FBS, pen/Strep and L-Glutamine. Cells were incubated overnight at either 30 
º C or 37 º C with 5% CO2, respectively. Cells were treated with respective compounds 1-4 at 
doses of 1, 10 or 100 µM (for 24 hours), followed by infection with DENV2 (MOI 1) for another 
24 hours. Each of the compound and respective doses were kept as six independent replicates in 
addition to the uninfected, infected and infected-DMSO treated controls. Following 24 hour post-
infection, cells were fixed with acetone-PBS mixture (3:1) for 20 min at -20 º C. Immediately 
after fixation, plates were air dried and washed with 1 x PBS and blocked with 5% FBS-PBS-
0.05% Sodium Azide for 15 min at RT. After blocking, cells were incubated with 4G2-
monoclonal antibody for overnight at 4º C. Cells were washed three times with PBS and 
incubated with Alexa-594 labeled mouse secondary antibody for 1 hour at RT, followed by 
washes (3X) with PBS. Plates were analyzed using EVOS fluorescence system 
(Invitrogen/Thermoscientific) and cells were scored for fluorescence or the presence or absence 
of infection in comparison to the positive (Infected and infected-DMSO-treated) or negative 
(uninfected) controls. Percentages were calculated from ratio of fluorescent cells and no 
fluorescent cells and as manual countings from eight microscopic fields. We collected eight 
images for each treatment and respective doses and representative images are shown in 
Supplementary information. Infection indicated by red fluorescence was determined as average 















Viral Plaque Formation Assay. Plaque assays were performed as described [36]. For the plaque 
formation assay, briefly, Vero cells were seeded into 6 well plates and at a density of 1.5 x 10
6
 
cells/well in DMEM complete medium with 10% FBS. Cells were incubated overnight at 37 º C 
with 5% CO2 and then treated with compounds 1-4 at doses of 100 µM (for 24 hours), followed 
by infection with DENV2 (MOI 1) for 2 hours. Following post-infection, medium was removed 
and warm 2% Seaplaque agarose (Lonza) overlay with complete DMEM media (1:1 ratio) 
containing antibiotic and antimycotics solution (1% each; Sigma) was added. Plates were 
incubated for additional 5 days, at 37 °C and 5% CO2. After an incubation period, plaques were 
stained with 0.03% of Neutral Red (Sigma) for 4 hours; stain was removed to count plaques. 
Each of the compounds (at the dose of 100 µM) was kept as two independent replicates in 
addition to the controls (infected and infected-DMSO treated). Representative images are shown 
for each compound and controls. Plaques counting are averages from three independent readouts. 
 
Isolation and culturing of mouse bone marrow-derived dendritic Cells. Bone marrow cells 
were isolated from femurs and tibias of C57BL/6 mice, and red blood cells were lysed with 
ammonium chloride.  Remaining cells were plated at a density of 7 x 10
6
 per 100-mm cell 
culture dish in 10ml of α-M M media (HyClone) supplemented with 10% Fetal Bovine Serum 
(Atlanta Biologicals), 2 mM L-glutamine, dextrose, essential and non-essential amino acids, 
sodium pyruvate, sodium bicarbonate, antibiotics, and 2-β-mercaptoethanol.  Granulocyte-
macrophage colony- stimulating factor (GM-CSF; Peprotech; 5ng/ml) was added at the time of 
plating, and again after 72 hours of incubation.  Experiments using animals were in accordance 
with protocols from the Institutional Animal Care and Usage Committee (as per the approved 













24 well plates as 1 x 10
5
 cells/ml in each well and infected with either DENV2/ZIKV (MOI = 1), 
respectively. After 24h post infection, dendritic cells were treated with all four compounds at 
different doses (1, 10, 100 µM) for another 24 hour, and collected for RNA extractions.  
 
Statistics. Statistical significance of differences observed in data sets was analyzed using Prism6 
software (GraphPad, La Jolla, CA) and Microsoft Excel. For data to compare two means, the 
non-paired, two-tail Student t test was performed for all analysis. P values of <0.05 were 
considered significant in all tests, error bars represent mean (+SD) values. Statistical test and P 





























Synthesis and Schemes of compounds. (E)-N-ethyl-2-[1-(thiazol-2-yl) 
ethylidene]hydrazinecarbothioamide (acetylethTSC) compound 1 was synthesized as described 
by Lewis et al.; [30] while the  compound 2, [Cu(acetylethTSC)Cl]Cl0.25C2H5OH 2  (where 
acetylethTSC = (E)-N-ethyl-2-[1-(thiazol-2-yl)ethylidene]hydrazinecarbothioamide) was 
synthesized as described by Sandhaus et al. [31] (Scheme 1, Supplementary Information). 
Compounds 3 and 4 were synthesized as described in (Scheme 2, Supplementary Information). 
The 
1
H NMR spectrum of compound 3 (citralEtTSC0.25C2H5OH) is shown in Supplementary 
Fig. 1A. The thiosemicarbazone ligand derived from 2-acetylethiazole (compound 1), 2-
acetylthiazole thiosemicarbazone ligand-copper(II) complex (compound 2), had been 
synthesized in [31]. Compounds 3 and 4 that are thiosemicarbazone ligands derived from citral 
without (compound 2) or with Co(III) complex (compound 4), respectively, were synthesized in 
this study as shown in schemes 1 and 2. Complexes 5 and 6, [Cu(phen)2]Cl2 and [Co(phen)3]Cl3, 
respectively, were synthesized in this study as by the literature procedure [34,35]. Schemes 3 and 
4 in Supplementary information show the synthesis of complexes 5 and 6. The 
1
H NMR 
spectrum of complexes 5 and 6 and [Co(phen)3]Cl3 are shown in Supplementary Fig. 1B and 1C. 
The methods used to synthesize these compounds are validated and are routinely been used in 
the biochemistry laboratory [31]. 
 
Thiosemicarbazone and 1, 10-Phenanthroline ligands conjugated with Cu(II) or Co(III) 
complexes enhance dengue virus loads. We determined the dengue virus loads in order to 













were infected with DENV2 (MOI = 1) for 24 hours, followed by 24-hour of incubations with 
respective compounds at different doses of 1, 10 and 100 µM concentrations. Q-PCR data 
showed that treatment of C6/36 cells with compounds 1 and 3 (100 µM) and compounds 2 and 4 
(10 and 100 µM) concentrations significantly (P<0.05) enhanced the DENV2 capsid mRNA 
transcripts in comparison to the infected-DMSO control (Fig. 1A). Immunoblotting analysis 
showed increased dengue envelope (E) protein loads in C6/36 cells treated with compound 2 or 4 
at all concentrations (1, 10 and100 µM) in comparison to DMSO-treated control (Fig. 1B). 
Human keratinocytes treated with compounds 2 and 4 (10 and 100 µM) also showed significant 
(P<0.05) increase in dengue capsid mRNA transcripts in comparison to the infected-DMSO-
treated control (Fig. 1C). However, compound 1 showed significantly increased dengue capsid 
mRNA transcripts at 100 µM treatment (Fig. 1C). Immunoblotting analysis with HaCaT cells 
revealed that compounds 2 and 4 (at 10 and 100 µM) showed dramatic increase in dengue E-
protein levels in comparison to the infected-DMSO treated control (Fig. 1D). Increased dengue 
virus E-protein loads were evident in compound 1-treated cells even at 100 µM concentrations in 
comparison to DMSO-treated controls. Total protein profiles serve as loading control and are not 
shown for comparison to the infected (untreated) or infected-DMSO treated samples (Fig. 1B & 
1D). In addition to compounds 2 and 4, we tested complexes 5 and 6 to find if coordination of 
copper(II) or cobalt(III) to these 1, 10-phenanthroline compounds also enhances DENV2 loads 
upon treatment. We found that in both mosquito and HaCaT cells, complexes 5 and 6 also 
enhanced DENV2 loads upon 24-hour treatment followed by 24 hour post-infection 
(Supplementary Fig. 2A and 2B). Viral loads were enhanced in a dose dependent manner when 
complexes 5 and 6 were treated at increasing concentrations of 1, 10, 100 µM (Supplementary 













Co(III) may itself enhance the DENV2 loads, we tested the CuCl2.2H2O and CoCl2.6H2O salts 
independently in both mosquito and HaCaT cells. We found that in both cell lines the salts alone 
did not enhanced the DENV2 loads at the similar treatments (with tested doses of 1, 10, 100 µM) 
and infection times (Supplementary Fig. 2C and 2D). This data suggested that Cu(II) or Co(III) 
salts alone has no effects as free cations. 
 
Cu(II) or Co(III) metal centers with thiosemicarbazone ligands enhance production of 
infectious viral particles. To further confirm the enhanced viral replication and increased 
DENV2 loads upon treatment with compounds (2 and 4), we performed the virus titration and 
plaque formation assays as described in methods. In both mosquito and HaCaT cells, virus 
titration assay showed percentage of infected cells (determined by fluorescent signals). Both 
compounds 2 and 4, showed significantly (P<0.05) increased percentage of infected cells at all 
tested doses of 1, 10 and 100 µM, for 24 hours of treatment followed by another 24 hour post-
infection period (Fig. 2A and 2B). All four compounds (1-4) at 100 µM treatment showed 
increased production of viral infectious particles in both mosquito and human cells (Fig. 2A and 
2B). However, compounds 2, 3 and 4 showed increased virus loads even at lower concentration 
of 10 µM in both cells (Fig. 2A and 2B). Representative images are shown for increased number 
of infected cells with pre-treatment of compounds 1-4 in both mosquito and HaCaT cells in 
comparison to their respective infected-DMSO treated controls (Supplementary Figures 3 and 4). 
The plaque formation assay further confirmed the increased production of viral plaques in Vero 
cells treated with compounds 1-4 at 100 µM (Fig. 2C and 2D). The plaques formed in the 
presence of compounds 3 and 4 were large with bigger diameter in comparison to the plaques 













showed several but smaller plaques in comparison to compound 1. The numbers of plaques 
formed were significantly increased upon treatment with compounds 2 and 4 in comparison to 
the compounds 1 and 3 (Fig. 2D). This data further confirmed that treatment with compounds 
containing Cu(II) or Co(III) metal centers increased production of infectious viral particles. Also, 
we analyzed the antiviral/cytokine response in DENV2-infected HaCaT cells treated with 
different compounds. Treatment of HaCaT cells with compound 1 (10 µM), showed significantly 
decreased levels of IFN-beta transcripts in comparison to infected-DMSO-treated control 
(Supplementary Fig. 5A). No differences were evident with the treatment with other compounds. 
In addition, we noted that treatment of HaCaT cells with compounds (1, 2 and 4) at 1 µM 
concentration showed significantly (P<0.05) decreased levels of TNF-alpha transcripts 
(Supplementary Fig. 5B). Due to the observation of increased viral replication upon treatment 
with compound 4, we determined whether treatment with this compound elicits similar effect in 
additional human cell lines such as HeLa cells. QPCR analysis revealed that HeLa cells 
treatment with compound 4 at 100 µM showed significantly (P<0.05) increased DENV2 loads, in 
comparison to the infected DMSO-controls (Supplementary Fig. 5C). 
 
Thiosemicarbazone ligands conjugated with Cu(II) or Co(III) enhance DENV2 and ZIKV 
loads in primary cultures of murine bone marrow derived dendritic cells. We next 
determined DENV2/ZIKV loads in the primary cultures of mouse dendritic cells isolated from 
bone marrow derived precursor cells. Dendritic cells were infected with either DENV2 or ZIKV  
(MOI = 1) for 24 hours, and then treated with compounds 1-4 at different doses (1, 10 and 100 
µM) for another 24 hours. QPCR analysis showed that both DENV2 (Fig. 3A) capsid transcripts 













compound 2 (both 10 and 100 µM treatments), however, unconjugated compound 1 showed 
significant (P<0.05) increase in only ZIKV loads. Compound 3 treatments (at 100 µM) showed 
enhanced viral loads in both DENV2 and ZIKV infected dendritic cells (Fig. 3A & 3B). In 
dendritic cells infected with DENV2, treatment with compound 4 showed a significant (P<0.05) 
increase in virus loads. However, treatments with compound 4 (100 µM) showed enhanced 
DENV2/ZIKV loads in comparison to their respective controls (Fig. 3A & 3B). 
 
Treatment with copper(II) conjugated compound post infection with ZIKV enhances viral 
burden in both mosquito and human cells. In C6/36 cells infected with ZIKV (MOI = 1; for 
24 h), followed by treatment with compounds 1-4 (at 1, 10 and 100 µM) for another 24 hours, we 
found that ZIKV loads (NS5 mRNA transcripts) were significantly (P<0.05) enhanced upon 
treatment with compound 2 (at 100 µM) (Fig. 4A). Although, no detectable levels of E-protein 
were evident in the same samples at MOI = 1 infectious dose (Fig. 4B). It was noted that in 
HaCaT cells, under similar conditions (ZIKV infection, MOI = 1, for 24hours; followed by 
compounds (1-4) treatments at 1, 10 and 100 µM for another 24 hours), ZIKV NS5 mRNA 
transcripts were significantly (P<0.05) increased upon treatment with compound 2, at both 10 
and 100 µM concentrations (Fig. 4C). Also, ZIKV E-protein loads were elevated upon treatment 
with compound 2 (at 100 µM) in comparison to the infected DMSO-treated controls (Fig 4D). 
Other compounds and their tested doses did not show any significant changes at either mRNA or 
protein levels (Fig. 4). We did not detected any ZIKV E-protein in infected and infected DMSO-
treated controls due to very low infection with MOI = 1. Total protein profiles serve as loading 













2 post infection with ZIKV enhance viral burden, whereas without conjugation the same 
compound 1 did not showed any enhancement in ZIKV loads.  
 
Since we did not find any detectable levels of E-protein in infected (untreated) or infected 
DMSO-treated controls at MOI = 1 of ZIKV infection, we performed additional experiments 
with higher infectious doses of MOI = 5. We first infected C6/36 cells or HaCaT cells with 
ZIKV at higher multiplication of infection of 5 for 24 hours, followed by treatments with 
compounds (1-4) at different doses of 1, 10, and 100 µM concentrations. We detected E-protein 
in all compound treatments including compound 2, and there were no differences in comparison 
to the infected DMSO-treated controls (Fig. 5A). When HaCaT cells were infected with MOI = 5 
of ZIKV in a similar manner, we detected E-protein in all samples including the infected 
(untreated) and infected DMSO-treated controls (Fig. 5B). We also included sodium salicylate 
(NaSal) compound that inhibits flavivirus replication [38] as control. NaSal-treated (5mM) cells 
showed inhibition of ZIKV replication and lower E-protein loads in both C6/36 cells and HaCaT 
cells (Fig. 5A & 5B). Total protein profiles serve as loading controls in both C6/36 cells and 
HaCaT cells (Fig. 5A & 5B). 
 
Pre-treatment with compounds 2 or 4 before infection with ZIKV enhance viral burden in 
both mosquito and human cells. To analyze if treatment with compounds before infection also 
enhance ZIKV replication in C6/36 and HaCaT cells, we first treated cells with compounds 1-4 
(at concentrations of 1, 10 and 100 µM) for 24 hours and then infected with ZIKV (MOI = 1) for 
another 24 hours. In C6/36 cells, treatment with Cu(II) or Co(III) conjugated- compounds 2 (10 













comparison to the infected (untreated) or infected DMSO-treated controls (Fig. 6A). It was also 
noted that ZIKV E-protein loads were enhanced in C6/36 cells treated with compound 2 (10 and 
100 µM) or 4 (100 µM) (Fig. 6B). In HaCaT cells, inductions in ZIKV loads were also noted in 
treatments with both Cu(II) or Co(III) conjugated compounds 2 and 4 (100 µM), respectively at 
100 µM concentration. In addition compound 1 (100 µM) also showed significant (P<0.05) 
induction in ZIKV NS5 loads in HaCaT cells (Fig. 6C). Immunoblotting showed that ZIKV E-
protein loads were enhanced upon treatment with compound 2 (100 µM) in comparison to the 
infected DMSO-treated control (Fig. 6D). No significant changes were observed with other 
compounds and the tested doses (Fig. 6D). Total protein profiles serve as loading controls (Fig. 
6C & 6D). E-protein levels were since not detected in infected DMSO-treated or infected 
untreated controls, we next analyzed effect of these compounds on ZIKV infection with higher 
infectious doses of MOI = 5. We treated C6/36 cells and HaCaT cells with compounds (1-4) at 
different doses of 1, 10, and 100 µM concentrations for 24 hours and then infected with ZIKV at 
higher infectious dose (MOI = 5) for another 24 hours. With increased infectious dosage both 
C6/36 cells and HaCaT cells, showed E-protein in all samples including the infected (untreated) 
and the infected DMSO-treated controls (Fig. 7). In C6/36 cells, no differences were noted 
between compounds 1-4, and in comparison to their respective infected DMSO-treated controls 
(Fig. 7A). However, a dose dependent enhancement of ZIKV loads was evident in HaCaT cells 
upon treatment with compounds 1-4 (Fig. 7B). Sodium salicylate treated (5mM) C6/36 cells and 
HaCaT cells serve as controls and show inhibition of ZIKV replication and lower E-protein 
levels (Fig. 7A & 7B). Total protein profiles serve as loading controls in both C6/36 cells and 
HaCaT cells (Fig. 7A & 7B). Collectively, these results suggest that Cu(II) or Co(III) conjugated 
















 Mosquito-borne diseases such as malaria, filariasis, arbovirus encephalitis and dengue are 
some of the major human health problems in tropical and subtropical countries. Recently, there 
has been an outbreak of ZIKV and Yellow Fever virus infections in the Americas. One of the 
potential interventions to combat mosquito-borne diseases is the continuous use of repellents in 
children and adults [7]. Our study suggests that use of Cu(II) or Co(III) containing metal centers 
in future preparations of food additives/repellents against mosquitoes may enhance replication 
and production of infectious viral particles of both DENV2 and ZIKV in the human cells upon 
transmission by the biting arthropods. Use of some insect repellents has been discouraged due to 
their adverse effects [3-8]. Safe use of alternatives like repellents of natural origin such as 
essential oils and their derived complex products has been preferred. Several studies have shown 
that plant based essential oils such as lemongrass; allspice oils, citral and other compounds are 
effective in controlling insect nuisance, mosquito bites and exhibit repelling properties [1,29,39-
41]. Repellent bioassays have revealed that the activity of lemon essential oils is due to the 
presence of citral component [42,43]. Our study has shown that thiosemicarbazone ligands 
derived from citral and 2-acetylethiazole and their conjugation with Co(III) or Cu(II), enhance 
ZIKV and DENV2 loads at both mRNA and protein levels, respectively. Testing of additional 
complexes 5 and 6 with 1, 10-phenanthroline ligands coordinated to Co(II) and Co(III) also 
showed similar increase in viral replication and DENV2 loads. Testing of “free” Cu(II) and 
Co(III) salts alone did not show any significant increase in DENV2 loads, suggesting no effects 













complexes might affect the antiviral or antimicrobial properties of such compounds. The reduced 
loads of IFN-beta suggested a diminished antiviral response in human cells (Supplementary Fig. 
5A).  
 
Several studies have shown that plant compounds have antiviral activities against dengue 
virus and other enveloped viruses [44-47]. However, conjugation of Co(III) or Cu(II) to such 
compounds may increase DENV2 loads in mosquito and HaCaT cells suggesting that both 
arthropod and human cells are susceptible to metal centers that may interfere and enhance 
DENV2 replication. In addition to human keratinocytes, human epithelial cells (HeLa cells) 
showed similar increase in DENV2 replication at 100 µM doses, suggesting similar activity of 
the compound 4 in enhancing viral loads (Supplementary Fig. 5C). Primary cultures of mouse 
bone marrow derived dendritic cells infected with DENV2/ZIKV also suggested that compounds 
2 and 4 increased viral replication at 100 µM concentration in other mammalian cells (Fig. 3B & 
3C). Infection with ZIKV, followed by treatment with compounds also showed similar results 
with compound 2, where 10 and 100 µM induced the ZIKV loads in both C6/36 cells and HaCaT 
cells (Fig. 4A & 4C). Although, upon treatment with compound 2, the ZIKV E-protein loads 
were higher in HaCaT cells (Fig. 4C & 4D), suggesting high susceptibility and less tolerance in 
presence of ZIKV with treatment of compounds conjugated to Cu(II) containing complexes. 
Increased infection with ZIKV (MOI = 5) showed that the E-protein loads in both mosquito and 
human keratinocytes had no changes in comparison to the loads of E-protein from the infected 
(untreated) or infected DMSO-treated controls. This data revealed that with higher infectious 
dose of MOI =5, and post-treatment of compounds after infection may moderately allow 














Pre-treatments with compounds 2 and 4 followed by ZIKV infection showed increased 
viral loads (NS5 mRNA transcripts) in both mosquito and human keratinocytes (Fig. 6A & 6C). 
However, the observation of higher loads of ZIKV E-protein in mosquito cells indicated greater 
replication of ZIKV in mosquito cells at all tested doses of compounds 2 and 4 (Fig. 6B). It was 
also noted that ZIKV loads in HaCaT cells (that were first treated with compounds 1, 2 and 4, 
followed by infection) were much higher when compared to the viral loads in HaCaT cells that 
were exposed to compounds after virus infection (Figs. 4C & 6C). It is assumed that when these 
Cu(II) or Co(III) conjugated compounds 2 & 4 are applied to normal human skin, there are 
greater chances of encountering enhancement in the ZIKV replication upon bites from infected 
mosquitoes. It was noted that HaCaT cells treated with compounds 1-4 for 24 hours, then 
followed by ZIKV infection at higher infectious doses (MOI = 5), showed a dose dependent 
increase of ZIKV E-protein levels with all tested compounds and their respective increasing 
doses (Fig. 7B). This data suggested that pre-exposure of human keratinocytes to these 
conjugated compounds might better enhance ZIKV loads when confronted through the infected 
mosquito bite. It is also intriguing to note that treatment with compound 2, followed by infection 
(with higher infectious dose of MOI = 5) with ZIKV, dramatically increased the viral loads in 
HaCaT cells (Figs. 7B), suggesting conjugation of Cu(II) or Co(III) complexes interference with 
ZIKV replication. Irrespective of the treatment procedures (infection followed by treatment with 
these compounds or pretreatment of compounds followed by infection) incubations lead to 
enhancement in DENV2/ZIKV loads in both arthropod and human cells.  This enhancement of 
DENV2/ZIKV infection suggest that Cu(II) or Co(III) complexes in food additives or repellent 













animals and aquatic environments. The mechanism of action of these compounds in enhancing 
DENV2/ZIKV loads in human keratinocytes is a future perspective. In summary, the present 
study shows that pre/post treatment with organic compounds containing Cu(II) or Co(III) metal 
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Figure 1. Treatment with organic compounds post infection enhances dengue virus loads. 
Q-PCR and immunoblotting analysis showing the DENV2 capsid transcripts or envelope E-
protein loads in C6/36 mosquito cells (A & B) or human keratinocytes (HaCaT cells) (C & D) 
infected with DENV2 (MOI = 1) for 24 hours followed by treatment with compounds 1-4 at 
different concentrations (1, 10 and 100 µM) for another 24 hours, respectively. DENV2 capsid 
mRNA transcript levels (A & C) were determined by Q-PCR upon treatment with compounds in 
comparison to the infected-DMSO controls. UT indicates untreated cells; M shows marker lane 
and µM means micro molar. Uninfected (UI) or infected (I) cells treated with DMSO are 
included as controls. DENV2 E- protein was detected in panels B & D and upper band indicates 
glycosylated form. Total protein profiles are shown as loading control and not for comparison. 
The differences in protein profiles are due to use of Colloidal Coomassie blue staining in panels 
with compounds 1 and 4 and Coomassie blue R-250 staining solution in panels with compounds 
2 and 3. Statistics was performed using the Student’s two-tailed test. The P<0.05 is indicated 
with an asterisk to show significance in comparison to DMSO-treated control and error bars 
indicate standard deviation. 
 
Figure 2. Treatment with compounds 2 and 4 increase DENV2 infectious titers and viral 
plaques. Virus titration assays in mosquito (A) and HaCaT (B) cells showing percentages of 
infected cells upon 24-hours treatment with compounds (1-4) at doses of 1, 10 and 100 µM, 
followed by infection with DENV2 (MOI 1) for another 24 hours. Percentage of infected cells 













treated controls and plotted as percentages. (C) Plaque formation assay performed in Vero cells 
treated with compounds 1-4 at 100 µM for 24 hours followed by infection with DENV2 (MOI 1) 
for 2 hours and incubation for another 5 days to form plaques are shown. A representative image 
of a 6-well plate with plaques from different groups is shown. Plaques from compounds treated 
groups were compared to the infected-DMSO-treated control. Ruler at the bottom determines the 
scale for the plaques from the representative image. (D) Quantitative assessment of number of 
plaques from compound (1-4) treated (100 µM) and infected-DMSO-treated is shown. 
Representative data from two independent experiments is shown. P value determined by 
Student’s two-tail t test is shown. 
 
Figure 3. Treatment of compounds enhances DENV2 and ZIKV loads in primary cultures 
of mouse bone marrow derived dendritic cells. 
Q-PCR analysis showing DENV2 loads in primary cultures of mouse bone marrow derived 
dendritic cells showing DENV2 (A) and ZIKV loads (B). 1 x 10
5
 Cells were infected with MOI 
= 1 of either DENV2 or ZIKV for 24 hours and followed by treatments with compounds 1-4 at 
different concentrations (1, 10 and 100 µM) for another 24 hours, respectively. DENV2 capsid 
mRNA transcript (A) and ZIKV NS5 mRNA transcript levels (B) were determined by Q-PCR 
upon treatment with compounds in comparison to the infected-DMSO controls. UT indicates 
untreated cells and µM means micro molar. Uninfected (UI) or infected (I) cells treated with 
DMSO are included as controls. ns indicates not significant. Statistics was performed using the 
Student’s two-tailed test. The P<0.05 is indicated with an asterisk to show significance in 














Figure 4. ZIKV loads are induced following post-treatment with organic compounds. Q-
PCR and immunoblotting analysis showing the ZIKV NS5 mRNA or E-protein loads in 
mosquito C6/36 cells (A & B) or human keratinocytes (HaCaT cells) (C & D) infected with 
ZIKV (MOI = 1) for 24 hours followed by treatment with compounds 1-4 at different 
concentrations (1, 10 and 100 µM) for another 24 hours, respectively. ZIKV NS5 mRNA 
transcript levels (A & C) were determined by Q-PCR upon treatment with compounds in 
comparison to the infected-DMSO controls. ZIKV E- protein was detected in panels B & D. 
Total protein profiles serves, as loading controls are not shown for comparison. UT indicates 
untreated cells and (UI) or (I) indicates uninfected or infected cells, respectively. M shows 
marker lane. Cells infected and treated with DMSO are included as controls. ns indicates not 
significant. Statistics was performed using the Student’s two-tailed test. The P<0.05 is indicated 
with an asterisk to show significance in comparison to DMSO-treated control and error bars 
indicate standard deviation. 
 
Figure 5. ZIKV loads are induced with higher infection following post-treatment with 
organic compounds. Immunoblotting analysis showing the ZIKV E- protein in C6/36 cells (A) 
or human keratinocytes (HaCaT cells) (B) infected with ZIKV (MOI = 5) for 24 hours followed 
by treatment with compounds 1-4 at different concentrations (1, 10 and 100 µM) for another 24 
hours, respectively. ZIKV E- protein was detected in panels B & D and upper band indicates 
glycosylated form. Total protein profiles serve as loading controls. UT indicates untreated cells 
and (UI) or (I) indicates uninfected or infected cells. M shows marker lane. Cells infected and 














Figure 6. Pre-treatment with organic compounds further enhanced ZIKV loads. Q-PCR and 
immunoblotting analysis showing the ZIKV NS5 mRNA or envelope E-protein loads in C6/36 
cells (A & B) or HaCaT cells (C & D) treated with compounds 1-4 at different concentrations (1, 
10 and 100 µM) for 24 hours followed by infection with ZIKV (MOI 1) for another 24 hours, 
respectively. ZIKV NS5 mRNA transcript levels (A & C) were determined by Q-PCR upon 
treatment with compounds in comparison to the infected-DMSO controls. UT indicates untreated 
cells and ns indicate not significant. Uninfected (UI) or infected (I) cells treated with DMSO are 
included as controls. M shows marker lane. Total protein profiles are not shown for comparison 
and serve as loading controls. Statistics was performed using the Student’s two-tailed test. The 
P<0.05 is indicated with an asterisk to show significance in comparison to DMSO-treated control 
and error bars indicate standard deviation. 
 
Figure 7. ZIKV loads are induced with higher infection dose following pre-treatment with 
organic compounds. Immunoblotting analysis showing the ZIKV E- protein in C6/36 mosquito 
cells (A) or human keratinocytes (HaCaT cells) (B) that were treated with compounds 1-4 at 
different concentrations (1, 10 and 100 µM) for 24 hours and followed by infection with ZIKV 
(MOI = 5) for another 24 hours, respectively. ZIKV E- protein was detected in panels B & D and 
upper band indicates glycosylated form. Total protein profiles serve as loading controls and M 
indicates marker lane. UT indicates untreated cells and (UI) or (I) indicates uninfected or 
















































































































Mosquito-borne diseases are of great concern to the mankind. Use of chemicals/repellents 
against mosquito bites and transmission of microbes has been the topic of interest from many 
years. Here, we show that thiosemicarbazone ligand(s) derived from 2-acetylethiazole or citral or 
1,10-phenanthroline upon conjugation with copper(II) or cobalt(III) metal centers enhances 
dengue virus (serotype 2; DENV2) and/or Zika virus (ZIKV) infections in mosquito, mouse and 
human cells. Enhanced ZIKV/DENV2 capsid mRNA or envelope protein loads were evident in 
mosquito cells and human keratinocytes, when pre-treated with compounds before/after 
infections. Also, treatment with copper(II) or cobalt(III) conjugated compounds increased viral 
titers and number of plaque formations. These studies suggest that conjugation of compounds in 
repellents/essential oils/natural products/food additives with copper(II) or cobalt(III) metal 
centers may not be safe, especially in tropical and subtropical places, where several dengue 
infection cases and deaths are reported annually or in places with increased ZIKV caused 
microcephaly. 
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